Sectoral Asset Management
Latest statistics and disclosures from Sectoral Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BMRN, LLY, OPCH, CNMD, PRVA, and represent 11.75% of Sectoral Asset Management's stock portfolio.
- Added to shares of these 10 stocks: CNMD (+$6.9M), GDRX (+$5.7M), BBIO, IOVA, ACAD, PGNY, RVMD, PODD, DCGO, ATEC.
- Started 15 new stock positions in EXEL, DXCM, VSTM, DCGO, GDRX, ATEC, IOVA, VTYX, RVMD, ACAD. STAA, BBIO, TSBX, VLTO, PGNY.
- Reduced shares in these 10 stocks: TMCI (-$9.7M), INSP (-$7.8M), AGTI (-$7.7M), TVTX (-$6.7M), GRTX (-$6.3M), AMLX (-$5.7M), APLS (-$5.3M), MLTX, Reata Pharmaceuticals Inc Cl A, TSVT.
- Sold out of its positions in SLRN, AGTI, BEAM, BMY, Eqrx, GRTX, INSP, Reata Pharmaceuticals Inc Cl A, SILK, TPST. TVTX, TMCI, TSVT.
- Sectoral Asset Management was a net seller of stock by $-27M.
- Sectoral Asset Management has $514M in assets under management (AUM), dropping by -14.38%.
- Central Index Key (CIK): 0001274413
Tip: Access up to 7 years of quarterly data
Positions held by Sectoral Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Sectoral Asset Management
Sectoral Asset Management holds 123 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Biomarin Pharmac Common (BMRN) | 2.5 | $13M | -2% | 145k | 88.48 |
|
Lilly Eli & Co Common (LLY) | 2.4 | $13M | -2% | 23k | 537.13 |
|
Option Care Health Common (OPCH) | 2.4 | $12M | -3% | 376k | 32.35 |
|
Conmed Corp Common (CNMD) | 2.2 | $12M | +150% | 114k | 100.85 |
|
Privia Health Group Common (PRVA) | 2.2 | $11M | -2% | 495k | 23.00 |
|
R1 RCM Common (RCM) | 2.2 | $11M | -8% | 744k | 15.07 |
|
Healthequity Common (HQY) | 2.0 | $11M | -21% | 144k | 73.05 |
|
Evolent Health Cl A (EVH) | 2.0 | $10M | -21% | 383k | 27.23 |
|
Radnet Common (RDNT) | 2.0 | $10M | -7% | 369k | 28.19 |
|
Atricure Common (ATRC) | 2.0 | $10M | 237k | 43.80 |
|
|
Amicus Therapeutics Common (FOLD) | 1.9 | $9.8M | +10% | 804k | 12.16 |
|
Axonics Common (AXNX) | 1.9 | $9.7M | +35% | 173k | 56.12 |
|
Inari Med Common (NARI) | 1.8 | $9.0M | -9% | 138k | 65.40 |
|
Johnson & Johnson Common (JNJ) | 1.7 | $8.9M | -8% | 57k | 155.75 |
|
Insmed Common (INSM) | 1.7 | $8.8M | -32% | 347k | 25.25 |
|
Unitedhealth Grp Common (UNH) | 1.7 | $8.5M | -26% | 17k | 504.19 |
|
Blueprint Medicines Common (BPMC) | 1.6 | $8.3M | +21% | 166k | 50.22 |
|
Prothena Corp SHS (PRTA) | 1.6 | $8.3M | +13% | 172k | 48.25 |
|
Icon SHS (ICLR) | 1.6 | $8.3M | -29% | 34k | 246.25 |
|
Mineralys Therapeuti Common (MLYS) | 1.6 | $8.0M | +36% | 841k | 9.51 |
|
Mirati Therapeutics Common (MRTX) | 1.5 | $7.9M | +22% | 182k | 43.56 |
|
Zentalis Pharmaceu Common (ZNTL) | 1.5 | $7.8M | +65% | 387k | 20.06 |
|
Amgen Common (AMGN) | 1.5 | $7.5M | 28k | 268.76 |
|
|
Immunogen Common (IMGN) | 1.4 | $7.4M | +6% | 464k | 15.87 |
|
Alkermes SHS (ALKS) | 1.3 | $6.8M | 244k | 28.01 |
|
|
Arcus Biosciences Common (RCUS) | 1.3 | $6.7M | +5% | 376k | 17.95 |
|
Intra Cellular Thera Common (ITCI) | 1.3 | $6.4M | +3% | 124k | 52.09 |
|
Vaxcyte Common (PCVX) | 1.2 | $6.2M | +11% | 121k | 50.98 |
|
Tenet Healthcare Common (THC) | 1.2 | $6.0M | 92k | 65.89 |
|
|
Abbvie Common (ABBV) | 1.1 | $5.9M | 39k | 149.06 |
|
|
Insulet Corp Common (PODD) | 1.1 | $5.9M | +193% | 37k | 159.49 |
|
Goodrx Hldgs Common (GDRX) | 1.1 | $5.7M | NEW | 1.0M | 5.63 |
|
Merck & Co Common (MRK) | 1.1 | $5.7M | 55k | 102.95 |
|
|
Moonlake Immunothera Class A (MLTX) | 1.1 | $5.6M | -46% | 98k | 57.00 |
|
Halozyme Therapeutic Common (HALO) | 1.1 | $5.6M | +4% | 146k | 38.20 |
|
Merit Medical Sys Common (MMSI) | 1.1 | $5.5M | +3% | 79k | 69.02 |
|
Olema Pharmaceutical Common (OLMA) | 1.1 | $5.4M | -32% | 438k | 12.35 |
|
Denali Therapeutics Common (DNLI) | 1.0 | $5.3M | +3% | 255k | 20.63 |
|
Boston Scientific Common (BSX) | 1.0 | $5.2M | 99k | 52.80 |
|
|
Pfizer Common (PFE) | 1.0 | $5.2M | 157k | 33.17 |
|
|
Glaukos Corp Common (GKOS) | 1.0 | $5.2M | 69k | 75.25 |
|
|
Alnylam Pharmacuetcl Common (ALNY) | 1.0 | $5.1M | -2% | 29k | 177.10 |
|
Abbott Labs Common (ABT) | 1.0 | $5.1M | +4% | 53k | 96.85 |
|
Lantheus Hldgs Common (LNTH) | 1.0 | $4.9M | -28% | 71k | 69.48 |
|
Vera Therapeutics Cl A (VERA) | 1.0 | $4.9M | 357k | 13.71 |
|
|
Bridgebio Pharma Common (BBIO) | 0.9 | $4.8M | NEW | 180k | 26.37 |
|
Rocket Pharmaceutica Common (RCKT) | 0.9 | $4.7M | +18% | 227k | 20.49 |
|
Replimune Group Common (REPL) | 0.9 | $4.6M | +13% | 271k | 17.11 |
|
Iovance Biotherapeut Common (IOVA) | 0.9 | $4.5M | NEW | 985k | 4.55 |
|
Karuna Therapeutics Common (KRTX) | 0.9 | $4.4M | 26k | 169.09 |
|
|
Acadia Pharmaceutcls Common (ACAD) | 0.9 | $4.4M | NEW | 210k | 20.84 |
|
Arrowhead Pharmaceut Common (ARWR) | 0.8 | $4.2M | +9% | 158k | 26.87 |
|
Tela Bio Common (TELA) | 0.8 | $4.2M | +194% | 525k | 8.00 |
|
Ptc Therapeutics I Common (PTCT) | 0.8 | $4.2M | -19% | 187k | 22.41 |
|
Progyny Common (PGNY) | 0.8 | $4.1M | NEW | 120k | 34.02 |
|
Ars Pharmaceuticals Common (SPRY) | 0.8 | $4.0M | -16% | 1.0M | 3.78 |
|
Revolution Medicin Common (RVMD) | 0.8 | $3.9M | NEW | 143k | 27.68 |
|
Biogen Common (BIIB) | 0.8 | $3.9M | +6% | 15k | 257.01 |
|
Iqvia Holdings Common (IQV) | 0.7 | $3.7M | -14% | 19k | 196.75 |
|
Thermo Fisher Sci Common (TMO) | 0.7 | $3.6M | 7.2k | 506.17 |
|
|
Humana Common (HUM) | 0.7 | $3.6M | +104% | 7.3k | 486.52 |
|
Intellia Therapeut Common (NTLA) | 0.7 | $3.6M | +11% | 112k | 31.62 |
|
Cytokinetics Common (CYTK) | 0.7 | $3.5M | 118k | 29.46 |
|
|
Docgo Common (DCGO) | 0.7 | $3.5M | NEW | 651k | 5.33 |
|
Shockwave Medical Common (SWAV) | 0.7 | $3.5M | -8% | 17k | 199.10 |
|
Edwards Lifescience Common (EW) | 0.7 | $3.4M | +37% | 49k | 69.28 |
|
Alphatec Holdings In Com New (ATEC) | 0.6 | $3.2M | NEW | 246k | 12.97 |
|
Medtronic SHS (MDT) | 0.6 | $3.1M | 40k | 78.36 |
|
|
Irhythm Technologies Common (IRTC) | 0.6 | $3.1M | +10% | 33k | 94.26 |
|
Regeneron Pharmctcls Common (REGN) | 0.6 | $3.1M | +16% | 3.7k | 822.96 |
|
Ventyx Biosciences I Common (VTYX) | 0.6 | $3.1M | NEW | 88k | 34.73 |
|
Madrigal Pharmaceuti Common (MDGL) | 0.6 | $3.1M | +10% | 21k | 146.04 |
|
Vertex Pharmaceuticl Common (VRTX) | 0.6 | $3.0M | +7% | 8.8k | 347.74 |
|
Ocular Therapeutix Common (OCUL) | 0.6 | $3.0M | +20% | 969k | 3.14 |
|
Dexcom Common (DXCM) | 0.6 | $3.0M | NEW | 32k | 93.30 |
|
Gilead Sciences Common (GILD) | 0.6 | $2.9M | +16% | 38k | 74.94 |
|
Danaher Corp Common (DHR) | 0.5 | $2.7M | 11k | 248.10 |
|
|
Scholar Rock Hldg Common (SRRK) | 0.4 | $2.2M | +26% | 310k | 7.10 |
|
Sarepta Therapeutics Common (SRPT) | 0.4 | $2.2M | -65% | 18k | 121.22 |
|
Annexon Common (ANNX) | 0.4 | $2.1M | +33% | 899k | 2.36 |
|
Turnstone Biologics Common (TSBX) | 0.4 | $2.0M | NEW | 518k | 3.94 |
|
Seagen Common | 0.4 | $2.0M | +14% | 9.2k | 212.15 |
|
Staar Surgical Common (STAA) | 0.4 | $1.9M | NEW | 47k | 40.18 |
|
Pmv Pharmaceuticals Common (PMVP) | 0.4 | $1.9M | -8% | 304k | 6.14 |
|
Macrogenics Common (MGNX) | 0.4 | $1.8M | +9% | 387k | 4.66 |
|
Spdr Ser Tr S&p Biotech (XBI) | 0.4 | $1.8M | +36% | 25k | 73.02 |
|
Atea Pharmaceuticals Common (AVIR) | 0.4 | $1.8M | +19% | 601k | 3.00 |
|
Allakos Common (ALLK) | 0.3 | $1.7M | +77% | 770k | 2.27 |
|
Iteos Therapeutics Common (ITOS) | 0.3 | $1.7M | +5% | 155k | 10.95 |
|
Astrazeneca Spn Adr (AZN) | 0.3 | $1.7M | +16% | 25k | 67.72 |
|
Verastem Common (VSTM) | 0.3 | $1.7M | NEW | 203k | 8.13 |
|
Moderna Common (MRNA) | 0.3 | $1.5M | +16% | 15k | 103.29 |
|
Sutro Biopharma In Common (STRO) | 0.3 | $1.5M | +7% | 432k | 3.47 |
|
Effector Therapeutcs Common (EFTR) | 0.3 | $1.4M | 2.4M | 0.60 |
|
|
Eyepoint Pharma Common (EYPT) | 0.3 | $1.4M | -43% | 176k | 7.99 |
|
Generation Bio Common (GBIO) | 0.3 | $1.4M | 357k | 3.79 |
|
|
Amylyx Pharmaceutic Common (AMLX) | 0.3 | $1.3M | -80% | 74k | 18.31 |
|
Rallybio Corp Common (RLYB) | 0.2 | $1.3M | 376k | 3.37 |
|
|
Bioatla Common (BCAB) | 0.2 | $1.2M | +26% | 706k | 1.70 |
|
Illumina Common (ILMN) | 0.2 | $865k | +15% | 6.3k | 137.28 |
|
Sanofi Spn Adr (SNY) | 0.1 | $688k | +17% | 13k | 53.64 |
|
Argenx Se Spn Adr (ARGX) | 0.1 | $603k | +16% | 1.2k | 491.63 |
|
Beigene Spn Adr (BGNE) | 0.1 | $599k | -42% | 3.3k | 179.87 |
|
United Therapeutics Common (UTHR) | 0.1 | $591k | +16% | 2.6k | 225.87 |
|
Incyte Corporation Common (INCY) | 0.1 | $557k | +17% | 9.6k | 57.77 |
|
Jazz Pharma Shs Usd (JAZZ) | 0.1 | $507k | +17% | 3.9k | 129.44 |
|
Royalty Pharma Shs Class A (RPRX) | 0.1 | $487k | +16% | 18k | 27.14 |
|
Neurocrine Bioscienc Common (NBIX) | 0.1 | $454k | +16% | 4.0k | 112.50 |
|
Legend Biotech Corp Spon Ads (LEGN) | 0.1 | $448k | -16% | 6.7k | 67.17 |
|
Ascendis Pharma A S Spn Adr (ASND) | 0.1 | $397k | +51% | 4.2k | 93.64 |
|
Biontech Se Spon Ads (BNTX) | 0.1 | $374k | +3% | 3.4k | 108.64 |
|
Roivant Sciences SHS (ROIV) | 0.1 | $356k | +19% | 30k | 11.68 |
|
Veralto Corporation Common (VLTO) | 0.1 | $309k | NEW | 3.7k | 84.56 |
|
Dr Reddys Labs Adr (RDY) | 0.1 | $301k | -43% | 4.5k | 66.87 |
|
Horizon Therapeutics SHS | 0.1 | $291k | -68% | 2.5k | 115.69 |
|
Medpace Holdings Common (MEDP) | 0.1 | $286k | +4% | 1.2k | 242.13 |
|
Exelixis Common (EXEL) | 0.1 | $273k | NEW | 13k | 21.85 |
|
Apellis Pharmaceutic Common (APLS) | 0.0 | $199k | -96% | 5.2k | 38.04 |
|
Fusion Pharmaceuti Common (FUSN) | 0.0 | $149k | 57k | 2.60 |
|
|
Arvinas Common (ARVN) | 0.0 | $138k | +13% | 7.0k | 19.64 |
|
Zai Lab Adr (ZLAB) | 0.0 | $73k | -62% | 3.0k | 24.31 |
|
Summit Therapeutics Common (SMMT) | 0.0 | $37k | -60% | 20k | 1.87 |
|
Arcutis Biotherapeutics Common (ARQT) | 0.0 | $23k | -69% | 4.4k | 5.31 |
|
Past Filings by Sectoral Asset Management
SEC 13F filings are viewable for Sectoral Asset Management going back to 2010
- Sectoral Asset Management 2023 Q3 filed Nov. 14, 2023
- Sectoral Asset Management 2023 Q2 filed Aug. 11, 2023
- Sectoral Asset Management 2023 Q1 filed May 12, 2023
- Sectoral Asset Management 2022 Q4 filed Feb. 10, 2023
- Sectoral Asset Management 2022 Q3 filed Nov. 10, 2022
- Sectoral Asset Management 2022 Q2 filed Aug. 15, 2022
- Sectoral Asset Management 2022 Q1 filed May 10, 2022
- Sectoral Asset Management 2021 Q4 filed Feb. 11, 2022
- Sectoral Asset Management 2021 Q3 filed Nov. 15, 2021
- Sectoral Asset Management 2021 Q2 filed Aug. 16, 2021
- Sectoral Asset Management 2021 Q1 filed May 14, 2021
- Sectoral Asset Management 2020 Q4 filed Feb. 12, 2021
- Sectoral Asset Management 2020 Q3 filed Nov. 13, 2020
- Sectoral Asset Management 2020 Q2 filed Aug. 13, 2020
- Sectoral Asset Management 2020 Q1 filed May 13, 2020
- Sectoral Asset Management 2019 Q4 filed Feb. 12, 2020